• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: E-News

E-News

Doctolib acquires Siilo, rebrands and brings its healthcare expertise to the Benelux

, 8 February 2024/in E-News /by panglobal

Siilo www.siilo.com , a leading medical messaging platform with over 550,000 users, is now globally rebranding to Doctolib Siilo, including the Netherlands and Belgium. This represents the successful integration of Siilo into Doctolib Siilo (Doctolib announced the acquisition of Siilo earlier in 2023). The rebranding also signals a future where Siilo benefits from the innovation […]

Read more
https://interhospi.com/wp-content/uploads/sites/3/2024/02/Doctolib-Siilo-scaled.jpg 1707 2560 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2024-02-08 08:38:492024-02-08 08:38:49Doctolib acquires Siilo, rebrands and brings its healthcare expertise to the Benelux

Aston University ARCHA programme wins £400,000 funding for new dementia research

, 8 February 2024/in E-News /by panglobal

The Aston Research Centre for Health in Ageing (ARCHA) at Aston University has received £400,000 in funding to recruit four PhD students for a dementia research programme. Four students will work on the Aston Brain Health Cohort Study (ABaHCoS), which will research tests for the early detection of dementia before symptoms become apparent. Two of […]

Read more
https://interhospi.com/wp-content/uploads/sites/3/2024/02/aston_uni_dementia.jpg 512 679 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2024-02-08 08:35:032024-02-08 08:35:03Aston University ARCHA programme wins £400,000 funding for new dementia research

Oncodesign Services, a leading European CRO in preclinical drug discovery acquires ZoBio, a CRO specialized in small molecule drug discovery

, 8 February 2024/in E-News /by panglobal

Oncodesign Services (ODS), a leading Contract Research Organization specialized in drug discovery and preclinical services, announces its international expansion through the acquisition of ZoBio, a Dutch CRO expert in biophysics-based small molecule drug discovery.  

Read more
https://interhospi.com/wp-content/uploads/sites/3/2024/02/shutterstock_1635975163-1-scaled.jpg 1440 2560 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2024-02-08 08:32:142024-02-08 08:32:14Oncodesign Services, a leading European CRO in preclinical drug discovery acquires ZoBio, a CRO specialized in small molecule drug discovery

Healthcare 21 Group (HC21) showcases cutting-edge support helping international MedTech manufacturers navigate UK market at Arab Health 2024

, 29 January 2024/in E-News /by panglobal

Healthcare 21 Group (HC21) will be at Arab Health 2024 to showcase their specialist support services designed to help international MedTech manufacturers navigate the UK market with confidence.

Read more
https://interhospi.com/wp-content/uploads/sites/3/2024/01/Nathan-Pettitt-Group-GM-.jpg 1000 1500 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2024-01-29 15:48:522024-01-29 15:48:52Healthcare 21 Group (HC21) showcases cutting-edge support helping international MedTech manufacturers navigate UK market at Arab Health 2024

Singapore robotics innovator OTSAW to showcase Camello+ multipurpose robot at Arab Health

, 29 January 2024/in E-News /by panglobal

Marking a pivotal point in a nine-year journey of innovation, OTSAW, a leader in Singapore’s robotics landscape, introduces Camello+, an autonomous mobile robot (AMR) poised to revolutionize various industries, including healthcare.

Read more
https://interhospi.com/wp-content/uploads/sites/3/2024/01/Camello-robot-scaled.jpg 1439 2560 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2024-01-29 08:40:452024-01-29 10:12:32Singapore robotics innovator OTSAW to showcase Camello+ multipurpose robot at Arab Health

Arab Health sells out as international exhibitors hit record levels

, 9 January 2024/in E-News /by panglobal

Arab Health will this year welcome over 40 country pavilions, including Serbia and Hong Kong, who will make their debut at the 2024 edition of the event  A total of 73 countries will be represented by exhibitors as Arab Health takes over the Dubai World Trade Centre, with a total of 25 halls occupied More […]

Read more
https://interhospi.com/wp-content/uploads/sites/3/2021/09/logo-Arab-Health.png 526 1280 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2024-01-09 13:40:172024-01-09 15:23:52Arab Health sells out as international exhibitors hit record levels

SyMRI 3D by SyntheticMR Set for Early 2024 Commercial Launch Post Obtaining CE-Marking

, 19 December 2023/in E-News /by panglobal

SyntheticMR announced that their next-generation imaging solution with isotropic 3D resolution, SyMRI 3D, has obtained approval in the EU and is now CE-Marked. With preparations in place, SyntheticMR eagerly anticipates the commercial launch of SyMRI 3D at the start of 2024.

Read more
https://interhospi.com/wp-content/uploads/sites/3/2023/12/CE-Mark-PR-Image-Filter.png 1080 1920 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2023-12-19 11:42:062023-12-19 11:42:06SyMRI 3D by SyntheticMR Set for Early 2024 Commercial Launch Post Obtaining CE-Marking

SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel

, 13 December 2023/in E-News /by panglobal

Phase IIa clinical trial evaluated Aurase Wound Gel in patients with venous leg ulcers Former Smith+Nephew CMO, Andy Weymann joins as Chairman to support progression of further Phase II clinical trials

Read more
https://interhospi.com/wp-content/uploads/sites/3/2023/12/SolasCureLogo.png 671 1500 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2023-12-13 09:58:542023-12-13 09:58:54SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel

Ergéa UK publishes white paper on potential of the modern Managed Equipment Services (MES)

, 8 December 2023/in E-News /by panglobal

Ergéa UK, vendor-neutral provider of Managed Equipment Services (MES), have announced the release of a comprehensive white paper that explores the evolution of MES and its role in helping to drive transformational change within healthcare organisations.

Read more
https://interhospi.com/wp-content/uploads/sites/3/2023/12/Ergea-Unlock-the-Potential-of-a-Modern-MES_pages-to-jpg-0001-scaled.jpg 2560 1811 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2023-12-08 12:30:352023-12-08 12:32:00Ergéa UK publishes white paper on potential of the modern Managed Equipment Services (MES)

Expanded Global Partnership for SyMRI 3D Announced by SyntheticMR and Philips

, 30 November 2023/in E-News /by panglobal

SyntheticMR announced expansion of their partnership with Philips to include SyMRI 3D. 

Read more
https://interhospi.com/wp-content/uploads/sites/3/2023/11/Screenshot-2023-11-30-at-10.32.10.png 994 1556 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2023-11-30 17:38:112023-11-30 17:39:13Expanded Global Partnership for SyMRI 3D Announced by SyntheticMR and Philips
Page 27 of 235«‹2526272829›»

Latest issue of International Hospital

April 2024

1 September 2025

Beta-blocker standard of care challenged by landmark heart attack trial

29 August 2025

SNMMI launches AI-powered trial finder for radiopharmaceuticals

28 August 2025

New non-invasive blood flow test outperforms standard Alzheimer’s diagnostic markers

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription